Ahead of the AGM Thursday, chief executive Tony Richardson said he was confident the group was on track to deliver full year revenues of €16mln (£13.2mln) and continue to generate free cash flows, in-line with market expectations.
Revenues for the period are expected to exceed €8mln (£6.6mln), almost double the €4.26mln (£3.5mln) reported last year.
In its final results, the group announced that its skin sciences arm, Innovenn, had made significant progress moving from its development phase into commercialisation.
Richardson said the group will provide an update on the repositioning of the Innovenn arm by July, but it had made excellent progress.
The group hopes to announce a new chair by the end of next month and is still in advanced discussions with suitable candidates.